Mechanism overviews · 29 papers
Peptidoteca
Readypep ↗
↳ Peptide Reference
Neuropeptide

Selank

Also known as: TP-7

A synthetic analogue of the immunomodulatory peptide tuftsin, studied in anxiolytic and neuro-research models.

Written by Peptidoteca Research Desk·Reviewed by Peptidoteca Research Desk·Last reviewed 2026-06-14·4 sources

§ In brief

Selank (also known as TP-7) is a synthetic analogue of the immunomodulatory peptide tuftsin, studied in anxiolytic and neuro-research models. It is supplied for laboratory research use only and is not approved for human or veterinary use. Its 7-residue amino-acid sequence is TKPRPGP.

What is Selank?

A synthetic analogue of the immunomodulatory peptide tuftsin, studied in anxiolytic and neuro-research models.

Selank is catalogued here as a reference compound for neuropeptide and cognitive research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

How is Selank studied?

Selank appears in the neuropeptide and cognitive literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 primary papers on Selank, each tagged with its study type below. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Is Selank approved for human use?

No. Selank is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

What are the research limitations?

Most available evidence for Selank is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Selank is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.

§ Primary literature

  1. 1.Vyunova TV (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters.ReviewThis review surveys the reported molecular aspects of the tuftsin-analogue heptapeptide Selank, summarizing described receptor interactions and proposed mechanisms underlying its anxiolytic-related activity reported in preclinical models.
  2. 2.Kolik (2019). Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine.Rodent studyIn a rat model of ethanol-induced memory impairment, administration of Selank (a peptide analogue of tuftsin) was associated with changes in brain-derived neurotrophic factor (BDNF) content in the hippocampus and prefrontal cortex, alongside changes in memory-related behavioral measures reported by the investigators.
  3. 3.Filatova E (2017). GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology.In-vitroIn cultured IMR-32 human neuroblastoma cells, Selank was reported to alter the expression of several genes involved in GABAergic neurotransmission relative to control conditions.
  4. 4.Kasian A (2017). Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology.Rodent studyIn a rat model of unpredictable chronic mild stress, the peptide Selank administered together with diazepam was associated with differences in anxiety-related behavioral measures relative to the comparator conditions tested. Findings are from a rodent behavioral paradigm only.
Compound spec
Sequence
TKPRPGP
Length7 aa
ClassNeuropeptide
CAS129954-34-3
Research vial10 mg

For in-vitro research only. Not medical, clinical or dosing advice.